glp 1 proteinuria Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis GLP-1 Receptor Agonists and Kidney

Invega Sustenna/Xeplion/Invega Trinza/Trevicta (paliperidone) Disease area(s): Psychiatry Manufacturer(s): Johnson & Johnson 2024 Sales (USD): $4.22 billion Why it sold so well: In 2024, J&Js long-acting antipsychotic portfolio including Invega Sustenna, Xeplion, Invega Trinza and Trevicta registered global sales of $4.22 billion, reflecting a 2.6% year-over-year increase

As a specialist Nutritional Therapist and Health Coach, my role is to help you make sense of that complexity, identify what works for you, and build sustainable changes that support your health long term

To an extent

2002 Apr [cited 2019 Jul 19];14:12331